Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

Authors:

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • Merck Healthcare KGaA
  • Pfizer
  • Merck

This publication has 8 references indexed in Scilit: